Clinical Trial Update: CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction [NA]

View source ↗

Summary

Clinical trial update on cytokine-induced killer (CIK) cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia, assessing the impact of earl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CIK cell therapy (cytokine-induced killer cells)

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | NA | Status: RECRUITING